|Back Zoom + Zoom - Top|
INNOVENT BIO-B (01801.HK)'s price has fallen around 8% since 28 June, against 4% rise in MSCI China healthcare index. JPMorgan noted continuous progress made by the company and saw no alarming sign after communicating with the management.
Given strong fundamentals, the price weakness offers an enticing buying opportunity. Overall, Innovent was reiterated Overweight at a price target of $33.
AAStocks Financial News
Web Site: www.aastocks.com